GoodRx CEO Wendy Barnes outlined the company's priorities at the 2025 JP Morgan Healthcare Conference in San Francisco.

Pet owners now have a new online resource that can help them save money. GoodRx, a company known for offering consumers ...

GoodRx released a list of 19 of the most influential drugs and vaccines approved by the FDA in 2024 to treat a variety of ...

Leerink Partners analyst Michael Cherny has maintained their bullish stance on GDRX stock, giving a Buy rating on January 10.Stay Ahead of the ...

Stay updated on the latest potential FDA drug approvals in 2025, including an expanded label for Ozempic and new, nonopioid painkillers.

Of the hundreds of drugs that entered the U.S. market in 2024, GoodRx has named 19 of them as the most notable. Note: The chronological list does not include December approvals. 1. Dupixent ...

GoodRx Holdings, Inc. (NASDAQ:GDRX – Get Free Report) dropped 8.4% during trading on Monday after Citigroup lowered their price target on the stock from $7.00 to $6.25. Citigroup currently has a buy ...

GoodRx returned to sequential growth in subscribers in Q3, showing potential for profit improvement. Read why I upgrade GDRX ...

GoodRx operates a telemedicine platform and a website that tracks prescription drug prices and provides coupons for discounts on medications. A national prescription-savings platform based in ...

GoodRx Holdings, Inc. (NASDAQ: GDRX) recently announced a Chief Financial Officer (CFO) transition in a Form 8-K filing submitted to the Securities and Exchange Commission. Karsten Voermann, the ...

2024 brought some major advancements in medicine. That includes the approval of "innovative" drugs like Tryvio for high blood pressure, Neffy for severe allergic reactions and Dupixent for chronic ...